---

NUTRITION - Park's Textbook of Preventive & Social Medicine

---

SECTION 1: PRINCIPAL FOODS

1. Cereals and Millets

• Rice: staple food of more than half the human race.
• Main source of energy (carbohydrates); ~350 kcal per 100 g.
• Contribute 70-80% of total energy and >50% of protein in typical Indian diets.
• Proteins are poor in quality - deficient in essential amino acid lysine.
• Maize proteins are additionally deficient in tryptophan (a niacin precursor) - hence pellagragenic.
• Some maize strains contain excess leucine which interferes with tryptophan → niacin conversion.
• When eaten with pulses, cereal and pulse proteins complement each other (cereal = lysine deficient, pulse = lysine rich).

• Nutritionally superior to rice and wheat in many respects.
• Ragi (finger millet): richest calcium source among millets (~344 mg/100g).
• Bajra: rich in iron and fat.
• All millets are gluten-free.

---

2. Pulses (Legumes)

• Contain 20-25% protein - double that of wheat, three times that of rice; higher protein by weight than meat, fish, or eggs.
• Quality is inferior to animal proteins - deficient in methionine and cysteine; but rich in lysine (complementing cereals).
• Soyabean is exceptional - up to 40% protein.
• Rich in minerals and B-group vitamins (riboflavin, thiamine).
• Dry pulses contain no vitamin C; germination raises vitamin C and B vitamins.
• Fermentation enhances riboflavin, thiamine, and niacin content and reduces antinutritional factors.
• Called "poor man's meat" in India.

---

3. Vegetables

• Green leafy vegetables (GLV): drumstick leaves, amaranth, spinach, fenugreek - richest plant sources of carotene, calcium, iron, riboflavin, folic acid, and vitamin C.
• Other vegetables: roots, tubers, gourds - important for variety.
• Low in energy; high water content.

---

4. Fruits

• Rich in vitamin C and carotene.
• Amla (Indian gooseberry): richest known natural source of vitamin C (~600 mg/100g).
• Guava: ~200 mg vitamin C/100g.
• Yellow/orange fruits (mango, papaya): rich in beta-carotene (pro-vitamin A).
• Banana: rich in potassium (~116 kcal/100g).

---

5. Milk and Milk Products

• Skimmed milk: fat removed; devoid of fat-soluble vitamins; excellent source of milk protein (35%) and calcium.
• Toned milk (Indian coinage): 1 part water + 1 part natural milk + 1/8 part skim milk powder. Composition similar to cow's milk; cheaper.
• Vegetable milk: prepared from groundnut or soyabean; used as substitute for animal milk.

---

6. Flesh Foods (Meat, Fish, Poultry, Eggs)

• Rich sources of high biological value (HBV) protein with all essential amino acids.
• Egg protein is the reference protein (Biological Value = 100); egg white contains avidin (antagonist of biotin).
• Fish: rich in omega-3 fatty acids, iodine (sea fish), and fluoride.
• Organ meats (liver, kidney): richest sources of vitamin A, iron, B12.

---

7. Fats and Oils

• Most concentrated energy source: 9 kcal per gram.
• Functions: energy provision, carrier of fat-soluble vitamins (A, D, E, K), source of essential fatty acids, improves palatability.
• Saturated fatty acids (SFA): butter, ghee, coconut oil, palm oil - raise LDL cholesterol.
• MUFA: olive oil, groundnut oil.
• PUFA: sunflower, safflower, soyabean oil - lower LDL.
• Omega-3 FA (EPA, DHA): fish oils, flaxseed - cardioprotective.
• Trans fatty acids (TFA): formed by hydrogenation; most harmful - raise LDL, lower HDL.

---

8. Sugar and Jaggery

• Pure energy sources; minimal other nutrients.
• Jaggery is preferable to refined sugar - contains iron, calcium, and B vitamins.

---

SECTION 2: NUTRITIONAL REQUIREMENTS

Key Definitions

1. Individual variability: RDA = Mean + 2 SD; covers 97.5% of population.
2. Bioavailability: For iron, dietary requirement is 20-30 times actual body requirement.

---

Energy Requirements

• PAR (Physical Activity Ratio) = Energy cost of activity per minute ÷ BMR per minute (unit-less; applicable to all ages and body sizes).
• PAL (Physical Activity Level): Overall daily activity summary.
• TEE (Total Energy Expenditure): Total energy per day.

• Lactation: additional ~500 kcal/day (0-6 months); ~400 kcal/day (6-12 months).
• Children: higher per-kg requirements due to growth.

---

Protein Requirements

• ICMR recommendation: 0.88 g/kg/day for adult males and females, assuming NPU (Net Protein Utilization) of 65 for dietary protein.

• Pregnancy: +1 g/day (1st trimester), +9.5 g/day (2nd trimester), +22 g/day (3rd trimester) (for 10 kg gestational weight gain).
• Lactation: +13 g/day (0-6 months) over normal.
• Children 0-6 years: higher per-kg requirement; most vulnerable to PEM.
• Elderly: requirements are not less than young adults.

• Protein estimates are valid only when energy requirements are fully met (inadequate energy → protein diverted to energy production).
• There are no body protein stores that can be replenished by high protein intake.

---

Essential Amino Acid Requirements (FAO/WHO/UNU 2007) - Adults

---

Fat and Carbohydrate Requirements

• Fat: minimum 15-20% of total energy; SFA should not exceed 10% of total energy; TFA intake as low as possible.
• Carbohydrates: should contribute 55-65% of total energy; complex carbohydrates preferred over refined sugars.
• Dietary fibre: 25-30 g/day recommended; prevents constipation, reduces CVD risk, helps manage diabetes.

---

Vitamin Requirements

---

Mineral Requirements

---

SECTION 3: BALANCED DIET

1. Adequacy - meets all nutrient requirements
2. Balance - correct proportions of all food groups
3. Caloric control
4. Nutrient density - more nutrients per calorie
5. Moderation - avoids excess of any single nutrient
6. Variety - foods from different groups

---

SECTION 4: FOOD PROCESSING & NUTRITIVE VALUE

---

SECTION 5: NUTRITIONAL ASSESSMENT (ABCD Method)

A - Anthropometric Methods

• Weight for age: identifies underweight; Gomez classification.
• Height for age: identifies stunting (chronic/past malnutrition).
• Weight for height: identifies wasting (acute/current malnutrition).
• MUAC (Mid-Upper Arm Circumference): field tool; <11.5 cm = SAM; 11.5-12.5 cm = MAM (children).
• BMI = Weight (kg) / Height (m)².

B - Biochemical Methods

C - Clinical Methods

D - Dietary Methods

---

SECTION 6: PROTEIN-ENERGY MALNUTRITION (PEM)

---

SECTION 7: MAJOR MICRONUTRIENT DEFICIENCIES

Vitamin A Deficiency (VAD)

• Leading cause of preventable childhood blindness.
• WHO Xerophthalmia Classification:
  • XN: Night blindness
  • X1A: Conjunctival xerosis
  • X1B: Bitot's spots
  • X2: Corneal xerosis
  • X3A: Corneal ulceration (<1/3 cornea)
  • X3B: Keratomalacia (≥1/3 cornea) → blindness
  • XS: Corneal scar
  • XF: Xerophthalmic fundus

• 1 lakh IU (100,000 IU) at 6-11 months
• 2 lakh IU (200,000 IU) at 12-59 months every 6 months

Iron Deficiency Anaemia (IDA)

• Most prevalent nutritional deficiency worldwide.

Iodine Deficiency Disorders (IDD)

• Spectrum: Goitre, cretinism, stillbirths, mental retardation, impaired cognitive development.
• Urinary iodine <100 mcg/L = iodine deficiency.
• Most serious consequence: Cretinism - irreversible mental retardation from fetal hypothyroidism.
• Prevention: Universal salt iodization (USI).

---

SECTION 8: NUTRITIONAL PROGRAMMES IN INDIA

---

QUICK REVISION - KEY FACTS

---

---

GENETICS IN PREVENTIVE MEDICINE — COMPLETE NOTES (Park's PSM)

---

1. INBORN ERRORS OF METABOLISM (IEM)

Substrate A → [Enzyme X] → Product B → Product C
                ↓ (enzyme deficient)
        A accumulates (toxic) + B/C deficient

Phenylketonuria (PKU)

• Inheritance: Autosomal recessive
• Defect: Deficiency of phenylalanine hydroxylase (PAH) → cannot convert phenylalanine → tyrosine
• Frequency: ~1 in 10,000 births
• Consequence: Phenylalanine accumulates → toxic effect on developing brain → mental retardation; phenylpyruvic acid appears in urine (hence the name)
• Screening: Guthrie test (bacterial inhibition assay) or tandem mass spectrometry on neonatal blood spot at 48-72 hours; blood phenylalanine >2 mg/dL = suspect PKU
• Treatment: Low-phenylalanine diet (restrict phenylalanine, supplement tyrosine) — if started early, prevents mental retardation; classic example of "treatable genetic disease"
• Maternal PKU: Elevated phenylalanine in a pregnant PKU woman is teratogenic to the fetus even if fetus is normal; dietary control essential before conception

Galactosaemia

• Defect: Deficiency of galactose-1-phosphate uridyl transferase (most common); galactose accumulates
• Features: Jaundice, hepatomegaly, cataracts, intellectual disability; symptoms appear when milk (lactose) feeding starts
• Treatment: Lactose-free diet (no breast milk, no cow's milk)

Maple Syrup Urine Disease (MSUD)

• Defect: Branched-chain keto acid dehydrogenase deficiency → accumulation of leucine, isoleucine, valine and their keto acids
• Features: Sweet/maple syrup smell to urine, feeding difficulties, encephalopathy, death if untreated
• Treatment: Branched-chain amino acid-restricted diet

Tay-Sachs Disease

• Defect: Hexosaminidase A deficiency → accumulation of GM2 ganglioside in neurons
• Inheritance: Autosomal recessive; high prevalence in Ashkenazi Jews
• Features: Progressive neurodegeneration, cherry-red spot on macula, blindness, seizures, death by age 4-5
• No treatment available; prevention by carrier detection and prenatal diagnosis

Alkaptonuria

• Defect: Deficiency of homogentisate oxidase → homogentisic acid accumulates
• First IEM described by Garrod (1902)
• Features: Dark urine on standing (oxidation of homogentisic acid), ochronosis (dark pigmentation of connective tissue), arthritis in later life

Homocystinuria

• Defect: Cystathionine beta-synthase deficiency → homocysteine accumulates
• Features: Marfanoid habitus, downward lens dislocation (vs Marfan's = upward), intellectual disability, thromboembolic events, osteoporosis
• Treatment: Vitamin B6 (in responsive cases), methionine restriction, folate, B12

---

2. CLASSIFICATION OF GENETIC DISORDERS

A. Chromosomal Disorders

• Due to abnormalities in chromosome number (aneuploidy) or structure (deletion, inversion, translocation)
• Incidence: 5.6 per 1,000 live births
• Sex aneuploidies: 2/1000; Autosomal aneuploidies: 1.7/1000; Translocations: 1.9/1000

• Trisomy: extra chromosome (non-disjunction during meiosis)
• Monosomy: missing chromosome

• Deletion: loss of chromosomal segment (e.g., Cri-du-chat — del 5p; short arm 5)
• Inversion: segment inverted 180°
• Translocation: segment transferred to another chromosome (Robertsonian: e.g., Down by translocation — 46 chromosomes but extra 21 material on chromosome 14)
• Isochromosome: duplication of one arm, deletion of other
• Ring chromosome: deletions at both ends, ends join

---

B. Single Gene (Mendelian / Unifactorial) Disorders

• One defective allele sufficient to cause disease
• 50% risk to offspring if one parent affected
• Pattern: vertical inheritance — appears in every generation
• Examples: Achondroplasia, Huntington's disease, Neurofibromatosis, Marfan's syndrome, Familial hypercholesterolaemia, Polycystic kidney disease (adult), Hereditary spherocytosis, Retinoblastoma, Polyposis coli, Brachydactyly

• Two defective alleles needed; carriers are unaffected
• 25% risk of affected child when both parents are carriers
• Pattern: horizontal — affected siblings; parents may be normal
• Examples: PKU, Galactosaemia, Tay-Sachs, Alkaptonuria, Cystic fibrosis, Sickle cell anaemia, Thalassaemia, Albinism, MSUD, Hurler syndrome, Wilson's disease, Haemochromatosis (most cases)

• Carrier females, affected males
• Sons of carrier female: 50% affected; daughters: 50% carriers
• Affected father cannot pass to sons; all daughters are obligate carriers
• Examples: Haemophilia A (Factor VIII) and B (Factor IX), Duchenne muscular dystrophy, Colour blindness (red-green), G6PD deficiency, Fabry's disease

• Rare; affected in every generation; affected males often more severely affected
• Examples: Vitamin D-resistant rickets (familial hypophosphataemia), Rett syndrome, Fragile X syndrome

• Both alleles expressed; e.g., ABO blood group, HbAS (sickle cell trait)

---

C. Multifactorial (Polygenic) Disorders

• Result from interactions of multiple genes AND environmental factors
• Most common type of genetic disorder
• Higher risk in relatives, proportional to number of affected relatives
• Examples: Hypertension, Coronary artery disease, Type 2 diabetes, Schizophrenia, Neural tube defects, Cleft lip/palate, Congenital heart disease, Pyloric stenosis, Club foot
• Features suggesting inherited predisposition: early onset; affected parent + sibling; occurrence in less commonly affected sex

---

3. GENETIC COUNSELLING

1. Helping the individual/family comprehend the medical facts
2. Appreciating how heredity contributes to the disorder
3. Understanding the risk of recurrence
4. Knowing what can be done about the risk
5. Making the best possible adjustment to the disorder

• Infectious and nutritional disorders have been brought under control
• Genetic disorders are serious public health problems (e.g., sickle cell anaemia in West Africa, thalassaemia in Mediterranean countries and India)

• Offered before affected child is born
• Premarital advice; carrier screening (e.g., thalassaemia in couples from high-prevalence areas)
• Avoidance of consanguineous marriages
• Less common in practice; ideal approach

• Most common type currently
• Offered AFTER genetic disorder has occurred in the family
• Sought most often for: congenital abnormalities, mental retardation, psychiatric illness, inborn errors of metabolism
• Options discussed: contraception, prenatal diagnosis and selective termination, sterilization (based on cultural/personal values — non-directive counselling)

1. Non-directive: Counsellor presents facts and options; does not impose decisions
2. Voluntary: Decisions rest with the couple
3. Confidentiality: Genetic information is private
4. Informed consent: Required for all tests and procedures
5. Psychological support: Addresses guilt, anxiety, grief

• Advanced maternal age (≥35 years)
• Previous child with chromosomal/genetic disorder
• Family history of genetic disease
• Consanguinity (blood relatives marrying)
• Recurrent miscarriages (≥3)
• Teratogen exposure in pregnancy
• Abnormal maternal serum screen or ultrasound finding
• Carrier detected by population screening (thalassaemia, sickle cell)
• Mother of haemophilia-affected child

---

4. PRENATAL DIAGNOSIS

1. Advanced maternal age (≥35 years) — risk of chromosomal aneuploidy
2. Previous child with chromosomal/structural anomaly
3. Parent is carrier of chromosomal rearrangement
4. Parent has autosomal dominant/recessive disorder
5. Family history of X-linked disorder (sex determination + specific diagnosis)
6. Abnormal maternal serum screening
7. Abnormal ultrasound findings
8. Consanguinity
9. Previous child with neural tube defect, metabolic disorder

---

Ultrasound (USG) in Prenatal Diagnosis

• Fluid-filled space at back of fetal neck
• NT ≥3.5 mm = increased risk of Down syndrome, other aneuploidies, cardiac defects
• Combined with maternal age, PAPP-A, free β-hCG = Combined First Trimester Screening
• Detection rate: ~85-90% for Down syndrome; 5% false positive

• Nuchal fold thickening (≥6 mm at 15-20 weeks)
• Echogenic bowel, echogenic intracardiac focus
• Choroid plexus cysts (associated with Trisomy 18)
• Renal pelvis dilatation
• Short femur/humerus
• Absent nasal bone

---

Chorionic Villus Sampling (CVS)

• Transcervical CVS: Through the cervix with catheter under USG guidance
• Transabdominal CVS: Through abdominal wall with needle under USG guidance

• Early diagnosis (1st trimester) → earlier, safer termination of pregnancy if required
• Results available in 7-14 days (full karyotype 2-3 weeks)
• Rapid FISH available in 24-48 hours for common aneuploidies

• Chromosomal disorders (karyotype from chorionic villi)
• Biochemical (enzyme assays for IEM)
• Molecular/DNA analysis (single gene disorders)

• Procedure-related miscarriage rate: ~1-2% (slightly higher than amniocentesis)
• Limb reduction defects: reported with CVS performed before 10 weeks (NOT seen after 10 weeks)
• Infection (chorioamnionitis), bleeding, amniotic fluid leakage
• Confined placental mosaicism (false positive/false negative result for fetal chromosome status)

---

Amniocentesis

1. Chromosomal analysis (karyotype of cultured amniocytes) — 2-3 weeks
2. Rapid FISH for common aneuploidies (24-48 hours)
3. Biochemical: AFP (elevated in NTD, abdominal wall defects); enzyme assays for IEM
4. Molecular genetics (DNA analysis): PCR for single gene disorders
5. Infection: PCR for CMV, toxoplasma

• Amniocytes: fetal cells shed from skin, GI tract, urogenital tract, amnion
• Must be cultured (2-3 weeks) for karyotype — limitation

• Elevated: Neural tube defects (open spina bifida, anencephaly), abdominal wall defects (gastroschisis, exomphalos), congenital nephrotic syndrome, fetal demise
• Low: Down syndrome (Trisomy 21)

• Procedure-related miscarriage: ~0.5-1% (lower than CVS)
• Amniotic fluid leakage, chorioamnionitis
• Needle injury to fetus (rare with USG guidance)
• Maternal Rh sensitization (anti-D prophylaxis needed for Rh-negative mothers)

---

Cordocentesis (Percutaneous Umbilical Blood Sampling — PUBS)

1. Rapid fetal karyotyping (results in 24-72 hours from lymphocytes — no culture needed)
2. Diagnosis of fetal haematological disorders (haemophilia, thrombocytopaenia, haemoglobinopathies)
3. Assessment of fetal anaemia (Hb measurement) — in Rh isoimmunization, hydrops fetalis
4. Intrauterine transfusion (therapeutic — same access)
5. Diagnosis of fetal infection (IgM antibodies, viral PCR)
6. Acid-base status in growth-restricted fetuses

• Karyotype rapidly (lymphocytes divide without long culture)
• Full blood count, coagulation factors
• Blood group, Rh typing
• Infection parameters

• Procedure-related miscarriage: 1-2%
• Fetal bradycardia, cord haematoma, fetal-maternal haemorrhage, infection
• Higher risk than amniocentesis

---

Non-Invasive Prenatal Testing (NIPT)

• Primary: Trisomy 21 (Down syndrome), Trisomy 18 (Edwards), Trisomy 13 (Patau)
• Secondary (extended panels): Sex chromosome aneuploidies (Turner, Klinefelter, XXX, XYY); microdeletion syndromes (DiGeorge/22q11.2, Angelman, Prader-Willi); fetal sex determination

• Detection rate: >99%
• False positive rate: <0.1% (much better than conventional biochemical screening)

• Non-invasive — no miscarriage risk
• Early (from 10 weeks)
• High sensitivity and specificity
• Can determine fetal sex (useful for X-linked disorders)

• Screening test, NOT diagnostic — abnormal NIPT must be confirmed by invasive testing (CVS/amniocentesis)
• Fails in 2-5% due to low fetal fraction (<4%)
• Cannot detect all chromosomal/structural anomalies
• Cannot detect NTDs or other structural defects
• More expensive than conventional screening
• Placental mosaicism can cause false results
• Not available widely in public health settings in India

---

5. NEWBORN SCREENING (NBS)

• Treatable or manageable
• Serious if untreated
• Common enough to justify screening cost
• Detectable before symptoms (presymptomatic phase)

1. Condition is an important health problem
2. Accepted treatment available
3. Facilities for diagnosis and treatment available
4. Recognizable latent/early symptomatic stage
5. Suitable test exists (sensitive, specific, acceptable)
6. Agreed policy on whom to treat
7. Cost economically balanced against other healthcare expenditure
8. Case-finding is a continuing process

• Heel prick at 48-72 hours after birth → blood spotted onto filter paper (Guthrie card)
• Stored, sent to lab for analysis
• Screening platform for many conditions simultaneously (tandem mass spectrometry/MS-MS)

• Simultaneously screens for 50+ conditions from a single blood spot
• Amino acid disorders (PKU, MSUD, homocystinuria, tyrosinaemia)
• Organic acidaemias
• Fatty acid oxidation defects (MCAD deficiency)
• Haemoglobin disorders

• Most common preventable cause of intellectual disability
• Incidence: 1 in 3,000-4,000 births
• TSH >20 mU/L on DBS → recall; >40 mU/L → treat
• Treatment with thyroxine started within 2 weeks of birth → normal intellectual development
• If untreated → cretinism (irreversible mental retardation, growth retardation)

• Not universally implemented; selective programmes exist
• Rashtriya Bal Swasthya Karyakram (RBSK): launched 2013; screens all children 0-18 years in government facilities for 4 D's — Defects at birth, Deficiencies, Diseases, Developmental delays/disabilities
• RBSK screens for 30 conditions including congenital hypothyroidism, hearing loss, vision defects, CHD, developmental delays, sickle cell disease, G6PD
• Uses 2 mobile health teams per block → screen in anganwadis, primary schools

---

6. PREVENTION OF GENETIC DISORDERS

Primary Prevention (Preventing occurrence)

• Genetic education in schools and for healthcare providers
• Population-wide awareness of common genetic disorders
• Avoiding consanguineous marriages (blood relatives marrying → increases risk of autosomal recessive disorders)
• Consanguinity risk: Cousin marriages → offspring have higher risk of autosomal recessive conditions (PKU, albinism, alkaptonuria etc.) and higher infant mortality
  • In one Japanese study: death rate 116/1000 (first 8 years of life) in offspring of first cousins vs 55/1000 in controls
• Maternal age: Early marriage of females reduces Down syndrome risk (1:3000 at age 20 vs 1:40 at age 40)

• Mutation prevention: Protect against mutagens:
  • Ionizing radiation (X-rays, gamma): gonadal shielding; avoid unnecessary X-ray in pregnancy; occupational protection
  • Chemical mutagens (benzene, pesticides, chemotherapy drugs): occupational exposure limits
• Folic acid supplementation: Prevents NTDs (see Section 8)
• Rubella vaccination: Congenital rubella syndrome causes heart defects, cataracts, deafness, microcephaly — MMR vaccine prevents this
• Prevention of Rh haemolytic disease: Anti-D immunoglobulin to Rh-negative mothers within 72 hours of delivery, after miscarriage, abortion, or invasive procedure

• Thalassaemia screening: Before marriage or in early pregnancy — CBC (microcytic hypochromic anaemia) + Hb electrophoresis; if both partners are carriers → 25% risk of thalassaemia major; offer prenatal diagnosis
• Sickle cell anaemia screening: In high-prevalence tribal communities (Maharashtra, MP, Gujarat, Odisha) — Sickling test + Hb electrophoresis
• Tay-Sachs screening: Ashkenazi Jewish population — hexosaminidase A enzyme assay
• G6PD screening: Before giving oxidant drugs (primaquine, dapsone, nitrofurantoin)

---

7. PRECONCEPTION CARE

1. Medical history review:
   • Chronic diseases (diabetes, hypertension, epilepsy, cardiac disease, thyroid disorders)
   • Family history of genetic disorders
   • Obstetric history (previous NTD, chromosomal anomaly, recurrent miscarriage, stillbirth)
   • Medications (teratogenic: valproate, retinoids, warfarin, lithium, ACE inhibitors)
2. Physical examination and investigations:
   • Blood pressure, BMI (optimize weight)
   • Haemoglobin (treat anaemia before pregnancy)
   • Blood group and Rh typing
   • Rubella immunity status (vaccinate if not immune — do not give MMR during pregnancy)
   • Syphilis, HIV screening
   • TSH (thyroid function — optimize before pregnancy)
   • Diabetes screening (HbA1c if diabetic — poor control is teratogenic)
   • Carrier screening (thalassaemia, sickle cell in high-risk populations)
3. Folic acid supplementation: Start 3 months before conception (see Section 8)
4. Lifestyle modification:
   • Stop smoking (causes IUGR, SIDS, placental complications)
   • Stop alcohol completely (fetal alcohol spectrum disorder — no safe level)
   • Avoid teratogenic drugs and herbal medicines
   • Achieve healthy weight (BMI 18.5-24.9)
   • Exercise regularly
5. Vaccination:
   • Rubella (MMR) — at least 1 month before conception
   • Varicella — if not immune
   • Hepatitis B — if not immunized
   • Tetanus toxoid
6. Genetic counselling (if relevant family/personal history)

---

8. ANTENATAL SCREENING

• AFP (Alpha-fetoprotein): Elevated in NTD, abdominal wall defects; Low in Down syndrome
• hCG: High in Down syndrome, low in T18
• uE3 (unconjugated estriol): Low in Down syndrome and T18
• Down syndrome pattern: ↓AFP, ↑hCG, ↓uE3
• T18 (Edwards) pattern: ↓AFP, ↓hCG, ↓uE3 (all low)
• Detection rate for Down syndrome: ~65-70% (triple); ~80% (quadruple)

---

9. FOLIC ACID SUPPLEMENTATION

• Anencephaly: Failure of rostral neural tube to close → absence of brain/skull → lethal
• Spina bifida (open/myelomeningocele): Failure of caudal tube to close → exposed spinal cord; causes paralysis, bladder/bowel dysfunction, hydrocephalus
• Encephalocele: Herniation of brain through skull defect
• Incidence: 1-2 per 1000 births; India has one of the highest rates

• Reduces risk of congenital heart defects
• Reduces risk of orofacial clefts
• May reduce risk of preterm birth, low birth weight
• Reduces homocysteine (cardiovascular risk factor)
• Under Anaemia Mukt Bharat: all pregnant women receive 500 mcg folic acid + 60 mg iron daily for 180 days

---

10. GENE THERAPY (BASICS)

• Somatic gene therapy: Genes introduced into body cells (e.g., bone marrow, lung cells); changes affect only the individual; currently used/studied clinically
• Germline gene therapy: Genes introduced into germ cells (eggs, sperm) or early embryo; changes are heritable and pass to future generations; ethically prohibited in most countries

• Viral vectors: Retroviruses (integrate into host DNA — stable), Adenoviruses (non-integrating, short-lived expression), Adeno-associated virus (AAV — preferred for most current trials), Lentiviruses
• Non-viral vectors: Liposomes, nanoparticles, naked DNA injection — less efficient but safer

• ADA-SCID (Severe Combined Immunodeficiency due to adenosine deaminase deficiency): First clinical gene therapy trial (1990, W. French Anderson); first approved gene therapy (Strimvelis, 2016 in Europe)
• Haemophilia A and B: AAV-based gene therapy (factor VIII, IX) — approved/in trials
• Sickle cell disease/Thalassaemia: Lentiviral vectors to correct HBB gene; also CRISPR-based reactivation of fetal haemoglobin
• Leber congenital amaurosis (retinal dystrophy): Luxturna (voretigene neparvovec) — first approved in vivo gene therapy (2017, FDA)
• Spinal muscular atrophy (SMA): Zolgensma (onasemnogene abeparvovec) — most expensive drug; single IV dose
• Duchenne muscular dystrophy: Exon skipping strategies

• Revolutionary gene editing tool; acts as "molecular scissors"
• Guide RNA directs Cas9 endonuclease to specific DNA sequence → cuts DNA → template repair or disruption
• Applications: research, somatic gene therapy, agriculture
• He Jiankui controversy (2018): First claimed germline CRISPR editing of human embryos (CCR5 gene — HIV resistance) in China → globally condemned; He was imprisoned

• Immune response to viral vectors
• Insertional mutagenesis (retroviral integration can cause oncogene activation)
• Short duration of expression (non-integrating vectors)
• Difficulty delivering to target tissues
• Off-target gene editing effects (CRISPR)
• High cost
• Ethical concerns (germline modification)

---

11. HUMAN GENOME PROJECT (HGP)

• Human genome contains approximately 3 billion base pairs of DNA
• Approximately 20,000-25,000 protein-coding genes (far fewer than initially estimated; humans have ~same as roundworm!)
• Only ~1.5% of genome codes for proteins; rest is non-coding ("junk DNA" — now known to have regulatory functions)
• 99.9% of DNA sequence is identical between any two humans — 0.1% variation accounts for all human diversity
• SNPs (Single Nucleotide Polymorphisms): ~10 million SNPs in human genome — useful as genetic markers

1. Disease gene identification: Identify genes responsible for single-gene disorders (e.g., BRCA1/2 for breast cancer; CF gene; HTT for Huntington's)
2. Pharmacogenomics: Tailor drug therapy based on individual genetic makeup (e.g., warfarin dosing, codeine metabolism, clopidogrel response)
3. Predictive medicine: Identify genetic risk for common diseases (T2DM, CVD, cancer)
4. Gene therapy: Provides targets for therapeutic intervention
5. Forensic medicine: DNA fingerprinting (STR analysis)
6. Evolutionary biology: Understanding human origins and migration
7. Drug development: Identify new drug targets based on gene function

---

12. ETHICAL, LEGAL AND SOCIAL ISSUES (ELSI) IN GENETICS

A. Key Ethical Issues

• Genetic information is unique — reveals information not just about the individual but about the entire biological family
• Risk of genetic discrimination by employers, insurance companies, educational institutions
• "Genetic exceptionalism" debate: Is genetic information fundamentally different from other medical information?
• Genetic Information Nondiscrimination Act (GINA, 2008, USA): Prohibits genetic discrimination in health insurance and employment

• Complex genetic information must be explained in understandable terms
• Consent for testing should be voluntary and autonomous
• Issues with predictive testing for late-onset conditions (e.g., Huntington's disease — no cure available)
• Right NOT to know one's genetic status

• Testing children for childhood-onset treatable conditions: acceptable (e.g., PKU, congenital hypothyroidism)
• Testing children for adult-onset non-treatable conditions (e.g., BRCA1, Huntington's): ethically controversial — generally deferred until adulthood so individual can make autonomous decision

• Testing for diseases like Huntington's (autosomal dominant, late-onset, no cure) raises profound questions
• Positive result (certainty of developing disease) causes severe psychological impact
• Requires pre- and post-test counselling; some choose not to be tested

• Companies like 23andMe offer genome-wide SNP tests directly to public
• Issues: interpretation without medical guidance, false reassurance/alarm, privacy of data (companies share/sell data), psychological harm, accuracy concerns

• Prenatal diagnosis + selective termination of affected fetuses → "negative eugenics" concerns
• Sex-selective abortion — deeply problematic; prohibited in India (PCPNDT Act)
• Pre-implantation Genetic Diagnosis (PGD): testing embryos before implantation in IVF — permits selection; "designer babies" debate
• Sex selection: Prohibited in India; PCPNDT Act, 1994 (Pre-Conception and Pre-Natal Diagnostic Techniques Act) — bans sex determination and sex-selective abortion

• Using gene therapy to treat disease: widely accepted as ethical
• Using genetic technology to enhance normal traits (intelligence, height, athleticism): ethically controversial and prohibited

• Therapeutic cloning: Create embryos for stem cells → for therapeutic purposes
• Reproductive cloning: Create genetically identical human being — universally banned

• Can genes be patented? (US Supreme Court: naturally occurring DNA sequences cannot be patented; cDNA can)
• Biopiracy concerns in developing countries

B. Key Legal Issues

1. PCPNDT Act, 1994 (Pre-Conception and Pre-Natal Diagnostic Techniques Act):
   • Prohibits sex determination of fetus (except for medical sex-linked diseases)
   • Prohibits sex-selective abortion
   • Regulates use of USG, amniocentesis, CVS, cordocentesis
   • All genetic clinics must register; maintain records
   • Violations: imprisonment up to 3 years; fine up to Rs.10,000; de-registration
   • Background: India's 1991 census showed alarming sex ratio decline in 0-6 year age group → evidence of widespread female feticide
2. Medical Termination of Pregnancy (MTP) Act, 1971 (amended 2021):
   • Permits termination up to 20 weeks on various grounds
   • 2021 amendment: Extends to 24 weeks for special categories (rape survivors, minors, fetal abnormalities incompatible with life, etc.)
   • For "substantial fetal abnormalities" diagnosed by Medical Board: no upper gestational limit
3. Prohibition of forced genetic testing / genetic discrimination: Not yet specifically legislated in India (unlike USA's GINA).
4. Regulation of GM organisms, gene therapy: Under review; ICMR and DBT (Department of Biotechnology) guidelines

C. Social Issues

• Genetic testing, NIPT, gene therapy are expensive → available only to the wealthy in India
• Risk of widening health disparities
• NBS programmes not uniformly available across India

• Prenatal diagnosis and selective termination may conflict with religious beliefs
• Attitudes to consanguinity differ across cultures (common in South India and some communities)
• Stigma of genetic disorders in marriage prospects (especially thalassaemia, sickle cell, mental retardation)

• Social stigma from genetic diagnosis
• Discrimination in marriage, employment, insurance
• Fear of stigmatization may prevent individuals from seeking genetic testing or disclosing results

• Risk of over-medicalizing normal human variation
• Reducing complex human traits to genes undermines appreciation of environmental and social determinants of health

• Large-scale biobanks and genomic databases raise issues of consent, data sharing, commercialization
• India Genome Variation (IGV) Project and GenomeIndia Project (2020): sequence 10,000 Indian genomes from diverse populations; concerns about privacy, informed consent of tribal/marginalized communities

D. Principles for Ethical Genetic Practice

1. Autonomy: Respect individual's right to make own decisions
2. Beneficence: Act in the best interest of the patient
3. Non-maleficence: Avoid harm; consider psychological consequences
4. Justice: Fair access to genetic services; non-discriminatory
5. Non-directiveness: In counselling — do not impose values; present options
6. Confidentiality: Protect genetic information
7. Informed consent: Voluntary, comprehensible, without coercion

---

QUICK REVISION TABLE

---

1. Textbook of Family Medicine, 9th Edition (Rakel) — isbn: 9780323239905
2. Swanson's Family Medicine Review — isbn: 9780323698115
3. Pfenninger and Fowler's Procedures for Primary Care, 3rd Edition — isbn: 9780323052672

• Narayan Reddy (Essentials) — exam favourite
• Parikh's — traditional standard
• Dikshit — widely used in many colleges

---

MENTAL HEALTH — COMPLETE NOTES (Park's PSM)

---

1. CONCEPTS OF MENTAL HEALTH

Definition (WHO)

---

Positive Mental Health

1. Positive self-concept: Acceptance of oneself; realistic awareness of strengths and limitations
2. Growth and development: Ability to develop one's full potential
3. Integration: Balance between various psychological processes; resisting stress
4. Autonomy: Self-determination; independence in decision making; inner-directedness
5. Reality perception: Perceiving the world accurately, free from distortion
6. Environmental mastery: Ability to love, work, play; adaptability; competence in solving problems

---

Mental Well-being

• Emotional well-being: Feeling happy, satisfied, positive affect, absence of negative emotion
• Psychological well-being: Self-acceptance, autonomy, personal growth, purpose in life, environmental mastery, positive relations with others (Ryff's 6 dimensions)
• Social well-being: Social acceptance, social actualization, social contribution, social coherence, social integration (Keyes)

---

Determinants of Mental Health

• Genetic predisposition (heritability of mental disorders)
• Neurobiological factors (neurotransmitter imbalances)
• Personality traits (resilience, coping styles)
• Gender (women: higher rates of depression, anxiety; men: higher suicide rates, substance use)
• Age (developmental stage — childhood adversity, adolescent vulnerability, elderly isolation)
• Physical health (chronic illness increases mental health risk)

• Family: warm, nurturing relationships vs conflict, abuse, neglect
• Peer relationships, social support
• Socioeconomic status: poverty, unemployment, food insecurity — major risk factors
• Education and literacy
• Housing (overcrowding, homelessness)
• Urban vs rural residence
• Exposure to violence, discrimination, war, disasters
• Social isolation and loneliness
• Culture and religion (protective or harmful depending on context)

• Early childhood experiences (adverse childhood events — ACEs)
• Attachment quality (secure vs insecure)
• Coping strategies (adaptive vs maladaptive)
• Resilience
• Self-esteem and locus of control

• The same social conditions that generate poverty and inequality also increase mental health risk
• Discrimination, marginalization, lack of control over one's life — all undermine mental health

---

2. BURDEN OF MENTAL DISORDERS

Global Magnitude

• Mental disorders are among the leading causes of disability worldwide
• ~1 billion people globally suffer from a mental disorder (WHO, 2022)
• Depression alone is the leading cause of disability worldwide (WHO)
• Mental, neurological, and substance use (MNS) disorders account for 13% of the global burden of disease (measured in DALYs)
• 4 of the 10 leading causes of disability worldwide are mental disorders: depression, alcohol-use disorders, schizophrenia, bipolar disorder
• Mental disorders cause 32.4% of years lived with disability (YLD) — the largest single contributor
• Only 1-2% of health budgets in low/middle-income countries are allocated to mental health

Magnitude in India

• National Mental Health Survey (NMHS, 2015-16): One of the largest mental health surveys in India
  • Estimated 150 million Indians need care for mental health conditions
  • Only 10-12% receive any treatment — massive treatment gap
  • Lifetime prevalence of mental disorders: 13.7%
  • Common mental disorders (CMD): 10.6%; Severe mental disorders (SMD): 1.9%
• Global Burden of Disease Study: Mental disorders contribute ~15% of total DALYs in India
• Treatment gap: >80% for most mental disorders in India

Disability Due to Mental Illness

• Depression: #1 cause of YLD globally
• Schizophrenia: severe disability; 80% cannot work productively
• Mental disorders are "disabling" rather than "killing" — most DALYs are from YLD, not YLL
• Exception: suicide — significant YLL contribution

Public Health Importance

1. High prevalence — affects 1 in 4 people globally at some point in their lifetime
2. Early onset — 50% of mental disorders begin by age 14; 75% by age 24
3. Chronic course — often lifelong, with relapses
4. Massive treatment gap — majority receive no care
5. Economic burden — lost productivity, caregiving costs
6. Social consequences — stigma, discrimination, human rights violations
7. Co-morbidity with physical illness — bidirectional relationship (e.g., depression ↑ CVD risk; diabetes ↑ depression risk)
8. Suicide — 800,000 deaths/year globally; 2nd leading cause of death in 15-29 year olds

---

3. COMMON MENTAL DISORDERS

Depression (Major Depressive Disorder — MDD)

• Depressed mood most of the day
• Loss of interest or pleasure (anhedonia)
• Fatigue, loss of energy
• Sleep disturbances (insomnia or hypersomnia)
• Appetite changes (decreased or increased) + weight change
• Psychomotor retardation or agitation
• Poor concentration, difficulty making decisions
• Feelings of worthlessness, guilt
• Recurrent thoughts of death, suicidal ideation

• Lifetime prevalence: 15-20% (women 2x more than men)
• Leading cause of disability globally (WHO)
• In India: ~4.5% (NMHS 2015-16)

• Major Depressive Episode (single/recurrent)
• Persistent Depressive Disorder (Dysthymia — chronic, ≥2 years)
• Postpartum Depression (within 4 weeks of delivery)
• Seasonal Affective Disorder (SAD)
• Psychotic depression

• Mild-moderate: Psychotherapy (CBT, interpersonal therapy) ± antidepressants
• Severe: SSRIs/SNRIs (first-line); TCAs; MAOIs; ECT for severe/refractory
• PHC level (DMHP): amitriptyline, fluoxetine available

---

Anxiety Disorders

---

Bipolar Disorder

• Distractibility
• Impulsivity/Indiscretion
• Grandiosity (inflated self-esteem)
• Flight of ideas / racing thoughts
• Activity increase / psychomotor agitation
• Sleep decreased (without feeling tired)
• Talkative (pressure of speech)

• Bipolar I: Full manic episodes ± depressive episodes (hospitalization often required during mania)
• Bipolar II: Hypomanic episodes (less severe than full mania) + depressive episodes
• Cyclothymia: Chronic fluctuating mood with hypomanic and depressive symptoms < full threshold

• Mood stabilizers: lithium (gold standard), valproate, carbamazepine, lamotrigine
• Acute mania: antipsychotics + mood stabilizer
• Acute depression: quetiapine, lurasidone; antidepressants with caution (risk of switching to mania)
• Psychoeducation essential for long-term management

---

Schizophrenia

• Lifetime prevalence: ~1% worldwide (one of the most uniform cross-cultural prevalences)
• Equal in men and women; earlier onset in men (late teens–20s) vs women (late 20s–30s)
• Leading cause of severe mental disorder disability

• Antipsychotics: typical (chlorpromazine, haloperidol) and atypical (risperidone, olanzapine, clozapine for refractory)
• Psychosocial: cognitive remediation, social skills training, family intervention
• Rehabilitation essential — most remain disabled without support

---

Substance Use Disorders

• Dependence/Addiction: Compulsive use despite harm; loss of control; withdrawal symptoms
• Tolerance: Increasing doses needed for same effect
• Withdrawal: Physical/psychological symptoms on stopping
• Harmful use: Use causing damage to physical or mental health without dependence

• Alcohol: Most common; estimated 14-20% of adult males drink; 2.6 crore dependent users (NMHS)
• Tobacco: ~28% of adults use tobacco (GATS 2017); leading preventable cause of death
• Cannabis (ganja, bhang): 2nd most common illicit drug
• Opioids: Heroin (North India, Punjab); opium; prescription opioid misuse
• Sedatives/hypnotics: Benzodiazepine misuse common
• Inhalants: Glue, petrol, whitener — common among street children

• CAGE questionnaire (Cut down, Annoyed, Guilty, Eye-opener) — screening
• AUDIT (Alcohol Use Disorders Identification Test) — WHO tool
• Withdrawal: tremors, seizures, delirium tremens (DTs) — medical emergency
• Complications: cirrhosis, Wernicke-Korsakoff syndrome, cardiomyopathy, fetal alcohol syndrome

• De-addiction: Detoxification (medically managed withdrawal) + rehabilitation
• Opioid substitution therapy (OST): methadone or buprenorphine for opioid dependence
• Nicotine replacement therapy (NRT): patches, gum; varenicline; bupropion
• Alcohol dependence: disulfiram (aversion), naltrexone (anti-craving), acamprosate
• Psychosocial: motivational interviewing, CBT, 12-step programmes (AA)
• Harm reduction: needle exchange programmes, naloxone availability

---

Dementia

• ~55 million people globally with dementia; projected to reach 150 million by 2050
• India: ~8.8 million (2020)
• Risk increases exponentially with age: doubles every 5 years after 65
• Dementia is the 7th leading cause of death globally (WHO)

---

Intellectual Disability (ID)

• Prenatal: genetic (Down syndrome, fragile X, PKU), infections (rubella, CMV), alcohol (FASD), iodine deficiency (cretinism)
• Perinatal: birth asphyxia, prematurity, kernicterus
• Postnatal: meningitis/encephalitis, head injury, hypothyroidism, severe malnutrition

---

4. RISK AND PROTECTIVE FACTORS

Risk Factors

• Genetic vulnerability (family history)
• Neurochemical imbalances (dopamine, serotonin, noradrenaline dysregulation)
• Prenatal exposure to infections, toxins, drugs
• Birth complications (hypoxia, low birth weight)
• Physical illness (especially chronic, disabling, painful conditions)
• Head injury, neurological disorders
• Female gender (depression, anxiety); male gender (substance use, suicide completion)
• Adolescence and old age (developmental vulnerabilities)

• Adverse childhood experiences (ACEs): abuse, neglect, witnessing violence
• Insecure attachment in childhood
• Cognitive distortions (negative thinking patterns)
• Poor coping strategies (avoidance, rumination)
• Low self-esteem
• Past psychiatric history

• Poverty and economic deprivation
• Unemployment / job insecurity
• Homelessness
• Social isolation, lack of support
• Domestic violence / intimate partner violence
• Conflict, war, displacement
• Bereavement, loss
• Discrimination (based on race, gender, sexual orientation)
• Substance use in family/peer group
• Urbanization and migration

Protective Factors

• Resilience and emotional regulation
• Good problem-solving and coping skills
• Positive self-esteem and self-efficacy
• Physical activity and healthy lifestyle
• Secure attachment style
• Education and literacy

• Warm, nurturing family relationships
• Social support networks (friends, community)
• Religious and spiritual beliefs (in many contexts)
• Economic stability

• Safe and stable living environments
• Access to quality education and employment
• Community cohesion and social capital
• Effective crisis support services
• Anti-stigma environment
• Culturally appropriate mental health services

---

5. PREVENTION OF MENTAL DISORDERS

Primordial Prevention

• Prevent the establishment of social, economic, and cultural patterns that contribute to mental disorders
• Policies addressing poverty, inequality, violence, discrimination
• School curricula promoting emotional literacy and life skills from early childhood
• Urban planning promoting community cohesion and social connectedness

Primary Prevention (Preventing new cases)

• Health promotion and education
• Life skills training (WHO Life Skills Education framework — see Section 6)
• Stress management programmes
• Parenting support programmes (e.g., parent-child interaction therapy)
• Home visiting programmes for at-risk families

• Periconceptional folic acid (prevents NTDs which can cause intellectual disability)
• Prevention of birth asphyxia (proper obstetric care)
• Universal iodization of salt (prevents cretinism)
• Immunization (prevents rubella, meningitis-related brain damage)
• Prevention of consanguinity
• Newborn screening (PKU, congenital hypothyroidism — early treatment prevents ID)

Secondary Prevention (Early detection and treatment)

• Mental Health Gap Action Programme (mhGAP): WHO initiative; trained non-specialist health workers to identify and treat priority mental disorders at PHC level
• Screening at PHC: PHQ-9 for depression; GAD-7 for anxiety; CAGE/AUDIT for alcohol
• Early intervention in psychosis: Within first 2 years of psychosis onset — reduces disability
• Suicide risk assessment: Identifying at-risk individuals at PHC and community level
• DMHP outpatient services at district hospitals
• School-based early detection of emotional/behavioural problems

Tertiary Prevention (Reducing disability)

• Rehabilitation of persons with chronic mental illness
• Social skills training, vocational rehabilitation, sheltered employment
• Family intervention and education (reduces relapse)
• Community-based rehabilitation (CBR)
• Halfway homes and supervised community residences
• Peer support groups

---

6. PROMOTION OF MENTAL HEALTH

Life Skills Education (WHO)

• Integrated into school curriculum — teaches children to manage emotions, relationships, stress
• Evidence-based: reduces substance use, aggression, bullying, teenage pregnancy, depression
• WHO and UNICEF promote Life Skills Education as key primary prevention strategy

---

Stress Management

• Problem-focused coping: Address the source of stress directly
• Emotion-focused coping: Manage the emotional response (mindfulness, relaxation)
• Relaxation techniques: Progressive muscle relaxation (Jacobson), deep breathing, yoga, meditation
• Mindfulness-Based Stress Reduction (MBSR): Jon Kabat-Zinn; evidence-based; reduces anxiety, depression, chronic pain
• Cognitive restructuring: Identify and challenge cognitive distortions (CBT)
• Physical activity: Proven antidepressant effect; 150 min/week moderate exercise
• Social support: Talking to trusted persons; peer support

---

Family and Community Support

• Family is the primary source of social support — protective against mental disorders
• Family psychoeducation: Educate family members about mental illness, treatment, relapse signs; reduces expressed emotion (EE) and relapse rates in schizophrenia
• Community mental health centres: accessible outpatient services
• Self-help groups: Peers with shared experiences (e.g., Alcoholics Anonymous, depression support groups)
• Community Awareness Programmes: reduce stigma; encourage help-seeking

---

School Mental Health

1. Life skills education — embedded in curriculum
2. Counselling services — trained counsellors or teachers
3. Teacher training — to identify children with emotional/behavioural problems
4. Anti-bullying programmes
5. Referral pathways — for children with identified problems to specialist services
6. Parent engagement — family involvement in school-based mental health

---

Workplace Mental Health

1. Feelings of energy depletion or exhaustion
2. Increased mental distance from one's job, cynicism
3. Reduced professional efficacy

1. Physical work environment (safety, ergonomics)
2. Psychosocial work environment (culture, stress, violence prevention)
3. Personal health resources (EAP, health promotion)
4. Enterprise community involvement

---

7. SUICIDE PREVENTION

Epidemiology

• ~800,000 deaths by suicide per year globally (WHO) = 1 death every 40 seconds
• 2nd leading cause of death among 15-29 year olds globally
• For every suicide, there are ~20 suicide attempts
• Low and middle-income countries account for >77% of suicides
• India: ~175,000 suicide deaths per year (NCRB 2022); crude suicide rate ~12-13/100,000
• Male: female ratio for suicide completion ~3-4:1 globally (men complete more; women attempt more)
• Most common methods in India: hanging, organophosphate poisoning (pesticide), self-immolation

Risk Factors for Suicide

• Previous suicide attempt (single strongest predictor)
• Mental disorder (present in ~90% of suicides) — especially depression, bipolar, schizophrenia, substance use disorders
• Hopelessness (more predictive than depression alone)
• Impulsivity and aggression
• Chronic physical illness (cancer, epilepsy, HIV, chronic pain)
• Family history of suicide

• Recent significant loss (bereavement, relationship breakdown, job loss)
• Financial crisis, debt, bankruptcy
• Social isolation
• History of trauma, abuse
• Access to means (firearms, pesticides, medications)
• Academic/examination stress (especially in India — farmers' suicide, student suicide)

• Economic recession
• Unemployment
• Disasters and conflicts
• Contagion/"Copycat" suicides (Werther effect — suicide following media reports)

• Strong social support (family, community)
• Religious beliefs and cultural values against suicide
• Access to mental health care
• Means restriction (safe storage of pesticides, medication)
• Positive coping skills
• Engagement in treatment
• Responsibility for children/pets

Warning Signs (SAD PERSONS scale — mnemonic)

• Talking about wanting to die or to kill oneself
• Looking for ways to kill oneself (researching methods, acquiring means)
• Talking about being a burden to others
• Saying there's no reason to live; hopelessness
• Giving away prized possessions
• Saying goodbyes; putting affairs in order
• Sudden calmness after period of depression (may indicate decision made)

Prevention Strategies

1. Limit access to means (means restriction): Pesticide storage regulations; gun control; barrier installation on bridges/buildings; blister packaging of medications; barriers on rail tracks
2. Interact with media for responsible reporting: Media guidelines for suicide reporting — avoid sensationalism, details of methods, glorification; include helpline numbers; "Papageno effect" (media stories of coping can protect)
3. Foster socio-emotional life skills in adolescents: School-based life skills, social-emotional learning
4. Early identify, assess, manage and follow up anyone who is affected: mhGAP; PHC training; crisis services

• Crisis helplines: iCall (TISS), Vandrevala Foundation, iCall — 24/7 telephonic support
• Gatekeeper training: Train teachers, primary care workers, police, community members to identify and respond to suicidal individuals
• Means restriction in India: Restricting sale of pesticides without prescription; safe storage; tablet packaging in small blister packs
• Decriminalization of suicide (MHA 2017): Section 309 IPC (attempt to suicide = criminal offence) — suspended; MHA 2017 states person who attempts suicide is under severe stress and needs care and rehabilitation, NOT punishment

Crisis Intervention

1. Immediate stabilization — ensure safety; remove lethal means
2. Active listening — empathic, non-judgmental communication
3. Assessment of risk level (low/moderate/high)
4. Problem identification — identify precipitating event
5. Generate alternatives — explore coping options
6. Action plan — agree on safety plan; contact person; follow-up appointment
7. Referral if needed (inpatient if high risk)

• Warning signs to look for
• Internal coping strategies
• Social contacts for distraction
• People to reach out to for support
• Professional contacts and crisis lines
• Making the environment safe (removing/securing means)

---

8. MENTAL HEALTH SERVICES

Community Mental Health

• Traditional model: Large psychiatric hospitals (custodial care, isolation from community)
• Modern model: Community-based care — services delivered where people live
• WHO advocates: "No health without mental health"; mental health integrated into general health services

• Outpatient services
• Crisis intervention
• Day care (partial hospitalization)
• Home visits
• Rehabilitation

• Reduces stigma (treatment in community, not asylum)
• Preserves social connections
• More accessible
• Less expensive
• Better long-term outcomes (community reintegration)

---

Primary Health Care Approach

1. PHC is accessible (closest to community)
2. Reduces stigma (attending general health facility)
3. Addresses comorbidity (mental + physical illness)
4. Cost-effective
5. Can be delivered by trained non-specialists (task-shifting)

• Launched 2008; updated 2016
• Provides evidence-based clinical guidelines for priority mental disorders that can be managed at PHC/non-specialist level
• Priority conditions: depression, psychosis, bipolar disorder, epilepsy, dementia, alcohol/substance use, suicide/self-harm, child/adolescent mental disorders, PTSD
• Training non-specialist health workers (doctors, nurses, ANMs, health workers) to identify and treat these conditions
• Implemented in 100+ countries; adopted in India under DMHP

• Screening with validated tools
• Basic pharmacological treatment (antidepressants, antipsychotics, mood stabilizers — available on Essential Medicines List)
• Counselling and psychosocial support
• Referral for complex cases
• Follow-up

---

Referral Services

---

Rehabilitation of Mentally Ill

1. Medical rehabilitation: Optimizing pharmacotherapy; minimizing side effects; ensuring adherence
2. Psychiatric rehabilitation: Skills training — activities of daily living (ADL), self-care, cooking, transportation
3. Social rehabilitation: Social skills training; family reintegration; reducing isolation
4. Vocational rehabilitation: Assess work capacity; supported employment; sheltered workshops; income-generating activities
5. Psychological rehabilitation: Cognitive remediation; CBT; psychoeducation

• Halfway homes (Group homes): Supervised community residences for those not yet ready for independent living
• Long-stay hostels: For those with no family support
• Day care centres: Structured daytime activities; therapeutic milieu without full hospitalization
• Clubhouse model: Member-run community centre offering social, educational, vocational support (Fountain House model)

• WHO defines CBR as a strategy for rehabilitation, equalization of opportunities, poverty reduction, and social inclusion of people with disabilities (including mental illness)
• Implemented through collaboration of family, community, government, and NGOs

---

9. NATIONAL MENTAL HEALTH PROGRAMME (NMHP)

Background and Launch

• Launched: 1982 by Government of India
• Developed on basis of experiences from Raipur Rani (Haryana) and Sakalwara (Karnataka) demonstration projects showing mental health can be integrated into PHC
• Currently covers 517 districts in 36 states/UTs

Aims of NMHP

1. Prevention and treatment of mental and neurological disorders and their associated disabilities
2. Use of mental health technology to improve general health services
3. Application of mental health principles in total national development to improve quality of life

Objectives

1. To ensure availability and accessibility of minimum mental health care for all in the foreseeable future — particularly to the most vulnerable and underprivileged sections
2. To encourage application of mental health knowledge in general health care and in social development
3. To promote community participation in mental health services development and stimulate efforts towards self-help in the community

Strategies

1. Integration of mental health with primary health care through the NMHP
2. Provision of tertiary care institutions for treatment of mental disorders
3. Eradicating stigmatization of mentally ill patients and protecting their rights through regulatory institutions (Central Mental Health Authority, State Mental Health Authority)

---

10. DISTRICT MENTAL HEALTH PROGRAMME (DMHP)

Background

• Launched as a pilot in 1996 in 4 districts (Bellary, Thiruvananthapuram, Imphal, Chandigarh)
• Based on WHO model of integrating mental health into district health services
• Expanded to all districts under 11th and 12th Five Year Plans
• Currently the backbone of mental health service delivery at district level in India

Components of DMHP

1. Training programmes: Train all workers in the mental health team at identified nodal institutes in the state (including medical officers, PHC staff, paramedical workers)
2. Public education in mental health: Increase awareness; reduce stigma; IEC activities
3. Early detection and treatment: OPD and indoor services at district hospital level; drug supply (amitriptyline, chlorpromazine, haloperidol, phenobarbitone — essential psychiatric medicines)
4. Community data collection: Provide valuable data and experience at community level for state and centre for future planning, service improvement, and research

Promotive and Preventive Activities (DMHP additions)

Key Personnel in DMHP (District Mental Health Team)

• Psychiatrist (1)
• Clinical Psychologist (1)
• Psychiatric Social Worker (1)
• Psychiatric Nurse (2)
• Case Registry Clerk

Rashtriya Kishor Swasthya Karyakram (RKSK)

• Adolescent health programme; includes mental health and life skills

National Tele Mental Health Programme (Tele-MANAS)

• Launched 2022 under Union Budget
• Toll-free helpline: 14416
• 24/7 multilingual mental health support
• 2-tier system: trained counsellors → mental health professionals
• Aims to bridge treatment gap, especially in rural/underserved areas

---

11. MENTAL HEALTHCARE ACT, 2017

Background

• Repealed the Mental Health Act, 1987
• Received Presidential assent: 7 April 2017; implemented: 29 May 2018
• Aligned with UN Convention on Rights of Persons with Disabilities (UNCRPD), ratified by India
• Key paradigm shift: From custodial, paternalistic approach → rights-based, person-centred approach
• Suicide decriminalized: Section 309 IPC (attempt to suicide) suspended; persons who attempt suicide are presumed to be under severe stress and will receive care/treatment, not punishment

Key Provisions

Rights of Persons with Mental Illness:

Advance Directive

• A person with mental illness can write an advance directive specifying:
  • How they wish to be cared for during mental illness
  • What treatment they accept or refuse
  • Who should be their nominated representative
• Must be registered with a notary/gazetted officer
• Mental health professionals and nominated representative must act in accordance with advance directive
• Significance: Respects autonomy even when person loses decision-making capacity during illness

Nominated Representative

• Person with mental illness can appoint a nominated representative (a person they trust) to make decisions on their behalf if they are unable to do so
• If no nominated representative appointed, family member in specified order acts as representative
• Nominated representative must act in the person's best interest and respect their wishes

Other Key Provisions

• Central Mental Health Authority (CMHA): Established at central level to regulate, maintain standards, collect data
• State Mental Health Authority (SMHA): At state level
• Mental Health Review Boards: At district level — review cases of involuntary admission; hear complaints; review advance directives
• Admission types:
  • Voluntary admission: Person themselves requests admission
  • Supported admission: Person lacks decision-making capacity; nominated representative requests; MHRB reviews
  • Independent admission (minors): For persons under 18; guardian admits
• Decriminalization of suicide: Major progressive step — persons who attempt suicide receive care, not imprisonment
• Insurance: Insurance companies must provide mental health insurance on same basis as physical health (parity)

---

12. ROLE OF HEALTH WORKERS IN MENTAL HEALTH

Early Identification

• Recognize signs and symptoms of common mental disorders (depression, psychosis, substance use) in community
• Use simple screening tools:
  • PHQ-2/PHQ-9: Depression screening
  • GAD-2/GAD-7: Anxiety
  • CAGE: Alcohol dependence
  • PSQ (Psychosis Screening Questionnaire)
• Identify suicidal ideation by direct questioning (does NOT increase risk — myth)
• Recognize child developmental problems, intellectual disability early

Referral

• Know the referral pathway (PHC → CHC → District Hospital DMHP → Medical College)
• Accompany patient and family to first appointment if needed
• Ensure continuity — communicate assessment and history to next level provider
• Know emergency referral criteria: psychosis, severe depression with suicidal risk, delirium, acute intoxication, first unprovoked seizure

Counselling

• Basic counselling skills (not psychotherapy — that requires specialized training):
  • Active listening
  • Empathy and unconditional positive regard
  • Non-judgmental attitude
  • Confidentiality
  • Problem-focused support
  • Motivational interviewing (for behaviour change — substance use, medication adherence)
• Psychological First Aid (PFA): Humane, supportive response to persons in crisis/disaster — Look, Listen, Link
• Adherence counselling: Ensure patients continue medication; address myths and misconceptions

Follow-up

• Home visits for patients who miss appointments or stop treatment
• Monitor for side effects of psychiatric medications
• Monitor for relapse signs; act on early warning signs
• Ensure family understanding and cooperation
• Monitor physical health (many psychiatric medications cause metabolic side effects)
• Record keeping and reporting

Community Awareness

• Anti-stigma activities in community
  • Correct myths: mental illness is not caused by supernatural forces; mentally ill are not violent; mental illness is treatable
• IEC (Information Education Communication) activities: health talks at AWC, schools, panchayats
• Promote help-seeking behaviour
• Celebrate World Mental Health Day (October 10) events
• Encourage persons to seek care early; reduce delay in treatment

---

13. REHABILITATION OF MENTALLY ILL PATIENTS

Principles

1. Individualized: Each patient has unique strengths, goals, and support systems
2. Recovery-oriented: Recovery is possible; goal is not just symptom control but meaningful life participation
3. Community-based: Delivered in and by the community where possible
4. Holistic: Addresses medical, psychological, social, vocational, spiritual needs
5. Rights-based: Person's rights, dignity, autonomy respected throughout
6. Family-inclusive: Family as partners in rehabilitation

Domains of Rehabilitation

Models of Rehabilitation

• Within psychiatric hospitals
• Occupational therapy, group therapy, skills training
• Transitional (aims for discharge to community)

• Supervised residential care for patients discharged from hospital but not yet ready for independent living
• Bridge between hospital and community
• 6-18 months typical stay
• Residents gradually take on responsibilities; learn independent living skills
• India: very limited — shortage of halfway homes is a major gap

• WHO/UNESCO/ILO joint position paper (2004)
• Strategy to ensure all persons with disabilities (including mental illness) have opportunity for education, employment, social participation
• Uses community resources; empowers family and community
• ANMs, ASHAs, community volunteers trained as CBR workers

• Structured therapeutic programme during day hours
• Patient returns home at night — preserves family ties
• Activities: group therapy, skills training, OT, recreational therapy
• Alternative to inpatient admission for subacute cases

• Multidisciplinary team delivers intensive mental health services in the community
• For people with severe mental illness (schizophrenia, bipolar) at risk of hospitalization
• Team includes psychiatrist, psychologist, social worker, nurse — available 24/7
• Evidence-based: reduces hospitalization, improves housing stability, quality of life

• Persons with lived experience of mental illness support others
• Powerful tool: reduces isolation, builds hope, role models recovery
• Integrated into many community mental health programmes

Recovery Model

• Recovery (Mental Health): Not just symptom remission but a deeply personal, unique process of changing one's attitudes, values, feelings, goals, skills, and roles. Living a satisfying, hopeful, and contributing life even with limitations caused by the illness.
• CHIME framework of recovery: Connectedness, Hope, Identity, Meaning/purpose, Empowerment

---

QUICK REVISION TABLE

---

---

EPIDEMIOLOGICAL STUDY DESIGNS — COMPLETE NOTES (Park's PSM)

---

CLASSIFICATION OF EPIDEMIOLOGICAL STUDIES

EPIDEMIOLOGICAL STUDIES
│
├── 1. OBSERVATIONAL STUDIES
│   ├── a. Descriptive Studies
│   └── b. Analytical Studies
│       ├── (i) Ecological / Correlational (population as unit)
│       ├── (ii) Cross-sectional / Prevalence (individual as unit)
│       ├── (iii) Case-control / Case-reference (individual as unit)
│       └── (iv) Cohort / Follow-up (individual as unit)
│
└── 2. EXPERIMENTAL STUDIES (Intervention Studies)
    ├── a. Randomized Controlled Trials (patients as unit)
    ├── b. Field Trials (healthy people as unit)
    └── c. Community Trials (communities as unit)

• Observational studies: Investigator measures but does NOT intervene; nature takes its own course
• Experimental studies: Investigator actively intervenes; attempts to change a disease determinant or progress of disease

---

1. DESCRIPTIVE STUDIES

Definition

Variables Described (Person-Place-Time)

• Age, sex, race/ethnicity
• Occupation, socioeconomic status
• Marital status, religion, customs
• Personal habits (smoking, diet, exercise)

• Geographic distribution (global, national, regional, rural/urban)
• International comparisons
• Local patterns (clustering — epidemic or endemic)

• Secular trends (long-term changes over years/decades)
• Seasonal variation (malaria peaks in monsoon)
• Cyclic/epidemic occurrence
• Point epidemics (short-duration outbreak)

Methods of Descriptive Epidemiology

1. Describing the clinical picture of disease (case reports, case series)
2. Examining the distribution of disease in terms of person, place, time
3. Measuring disease frequency using rates (incidence, prevalence, mortality)
4. Cross-sectional studies (surveys of population at one point in time)
5. Comparing with known indices (compare rates across populations/subgroups to identify high-risk groups)
6. Formulating hypotheses — descriptive data generates hypotheses which are then tested by analytical studies

Ecological (Correlational) Studies

• Unit of analysis = populations (not individuals)
• Examine relationship between exposure levels and disease rates across different populations or geographic areas
• Example: Correlation between per capita fat consumption and breast cancer rates across countries
• Ecological fallacy (fallacy of wrong level): Association seen at population level may not hold at individual level — major limitation
• Quick, inexpensive, use routinely collected data (health statistics)
• Generate hypotheses but cannot establish causation

Cross-Sectional Studies (Prevalence Studies)

• Snapshot in time ("a photograph, not a cine film" — Park)
• Measures prevalence (not incidence)
• Both exposure and disease status determined simultaneously
• Can study multiple risk factors and outcomes in one survey

• Prevalence of disease in population
• Distribution of disease by age, sex, place
• Association between exposure and disease (but not causal direction)
• Burden for health service planning

• Temporal sequence (exposure before disease?) — hence cannot establish causation
• Incidence rate (new cases)
• Natural history of disease

• Planning health services and allocating resources
• Assessing burden of disease
• Identifying high-risk groups
• Hypothesis generation for analytical studies
• Monitoring and evaluation (nutrition surveys, NFHS)

• Prevalence-incidence bias: Captures survivors, not those who died or recovered early → overestimates slowly progressing diseases; underestimates rapidly fatal ones
• Cannot determine causality (no temporal sequence)
• Unsuitable for rare diseases (need huge sample) or short-lived conditions
• Response bias

Uses of Descriptive Epidemiology (summary)

1. Describe the health status of the community
2. Provide clues to disease aetiology
3. Formulate hypotheses for analytical testing
4. Provide basis for planning, evaluating, and resource allocation
5. Identify high-risk groups for targeted interventions
6. Monitor trends in disease frequency over time

---

2. ANALYTICAL STUDIES

Definition

1. Case-control study
2. Cohort study

---

A. CASE-CONTROL STUDY

Other Names

• Retrospective study
• Case-reference study
• Trohoc study (cohort spelled backwards — opposite direction)

Definition

Three Distinctive Features (Park's)

1. Both exposure AND outcome (disease) have already occurred before the study begins
2. Study proceeds backwards — from effect to cause (retrospective direction)
3. Uses a control or comparison group to support or refute the inference

Direction of Inquiry

Past ←────────────── Present
Exposure          Disease
(Look back)
Cases (diseased) → Were they exposed?
Controls (non-diseased) → Were they exposed?

Basic Design — The 2×2 Contingency Table

Measure of Association: ODDS RATIO (OR)

• OR = 1: No association
• OR > 1: Positive association (exposure increases risk)
• OR < 1: Negative association (exposure reduces risk — protective)
• OR approximates RR when the disease is rare (rare disease assumption)

• Cases: lung cancer patients; Controls: non-lung cancer hospital patients
• Exposure: cigarette smoking
• If smoking found more frequently in cases than controls → OR > 1 → smoking associated with lung cancer

Selection of Cases

• Clear operational case definition (diagnostic criteria must be specified)
• Incident cases (newly diagnosed) preferred over prevalent cases (avoid prevalence-incidence bias)
• Sources: hospital-based (convenient but may not represent community cases) or population-based (better but harder to identify)

Selection of Controls

• Free of the disease under study
• Drawn from the same population from which cases arose
• Comparable to cases in characteristics other than the exposure under study

1. Hospital controls (other patients in same hospital) — convenient but risk of Berkesonian bias
2. Community/neighbourhood controls — population-based, representative but expensive
3. Friend/relative controls — share similar social background
4. Dead controls (rare) — from mortality records

• Individual matching: Each case matched to one or more controls on specific characteristics
• Group/Frequency matching: Controls selected so that overall distribution of confounders is similar to cases

Bias in Case-Control Studies

Advantages of Case-Control Studies

1. Relatively easy and quick to conduct
2. Inexpensive compared to cohort studies
3. Require fewer subjects
4. Suitable for rare diseases (start with cases — don't need to follow large population)
5. No risk to subjects (purely observational)
6. Can study multiple risk factors simultaneously for one disease
7. No attrition problems (no follow-up required)
8. Ethical problems minimal
9. Results available quickly

Disadvantages of Case-Control Studies

1. Prone to bias (especially recall and selection bias)
2. Cannot calculate incidence or relative risk directly
3. Information on past exposure relies on memory or records — accuracy uncertain
4. Selection of appropriate control group is difficult — a major challenge
5. Temporal sequence not clearly established — hard to prove exposure preceded disease
6. One outcome only per study — cannot study multiple diseases simultaneously
7. Unsuitable for rare exposures
8. Cannot estimate disease incidence in exposed vs unexposed

Classic Examples of Case-Control Studies

• Doll and Hill (1950): Smoking and lung cancer (first major case-control study)
• Herbst et al. (1971): DES (diethylstilboestrol) exposure in pregnancy and vaginal adenocarcinoma in daughters
• Jick et al.: Oral contraceptives and thromboembolic disease
• Snow (1854): Cholera cases vs non-cases → Broad Street pump water source identified

---

B. COHORT STUDY

Other Names

• Prospective study
• Longitudinal study
• Incidence study
• Follow-up study
• Forward-looking study

Definition

Three Distinctive Features (Park's)

1. Cohorts identified prior to appearance of disease (disease-free at start)
2. Study groups observed over time to determine frequency of disease
3. Study proceeds forwards — from cause to effect

Direction of Inquiry

Present ──────────────→ Future
Exposure              Disease
(Follow forward)
Exposed group → Do they develop disease?
Non-exposed group → Do they develop disease?
Compare incidence rates

Basic Design — 2×2 Table

Concept of Cohort

• Birth cohort: All born in same year (e.g., birth cohort of 2000)
• Exposure cohort: All exposed to a common drug, vaccine, or risk factor
• Marriage cohort: All married in same period
• Occupational cohort: All workers in same factory/industry

Measure of Association: RELATIVE RISK (RR) / RISK RATIO

• RR = 1: No association
• RR > 1: Exposure increases risk
• RR < 1: Exposure reduces risk (protective)

• Measures the excess risk attributable to the exposure
• Has public health relevance — if exposure eliminated, how much disease prevented?

• Measures the burden of disease attributable to the exposure in the total population

Types of Cohort Studies

• Exposure has occurred; disease has NOT yet occurred at study start
• Cohort assembled now → followed forward in time
• Example: Framingham Heart Study (assembled healthy people → followed for CVD); Doll & Hill study of smoking and lung cancer in British doctors
• Most valid but expensive and time-consuming

• Both exposure AND disease have ALREADY occurred before study starts
• Investigator goes back in time (using old records) → reconstructs cohort → traces them to present
• Also called: historical cohort, non-concurrent prospective, prospective study in retrospect
• Example: Study of lung cancer in uranium miners using employment records from 1940s; study of angiosarcoma of liver in PVC workers
• Quicker and cheaper than prospective; relies on completeness of historical records

• Retrospective component (past records) + prospective component (continue follow-up forward)

Indications for Cohort Studies (Park's)

1. Good evidence of association already exists (from descriptive + case-control studies)
2. Exposure is rare but incidence of disease is high among exposed (e.g., occupational exposures)
3. Attrition can be minimized (stable, cooperative, accessible cohort)
4. Adequate funds are available

Advantages of Cohort Studies

1. Temporal sequence clearly established — exposure definitely precedes disease
2. Can directly calculate incidence rates and relative risk
3. Can calculate attributable risk
4. Can study multiple outcomes (diseases) from a single exposure
5. Recall bias avoided — exposure status determined before disease occurs
6. Allows complete description of the natural history of disease
7. Rare exposures can be studied (select large exposed group)
8. Less prone to selection bias

Disadvantages of Cohort Studies

1. Time-consuming — must wait for disease to develop (years to decades)
2. Expensive — large samples, long follow-up, many outcome measurements
3. Attrition (loss to follow-up): Those who drop out may differ systematically from those who remain → bias; every effort must be made to minimize losses
4. Not suitable for rare diseases (need enormous sample to observe enough cases)
5. Design may become outdated — advances in diagnosis/classification during long study period
6. Hawthorne effect — being observed may change behaviour of cohort members

Classic Examples of Cohort Studies

• Framingham Heart Study (USA, 1948 onwards): Long-term cohort study of CVD risk factors; identified hypertension, hyperlipidaemia, smoking, diabetes as CVD risk factors
• Doll and Hill (1951): Prospective study of 40,000 British doctors — smoking and lung cancer; gold-standard evidence
• Royal College of General Practitioners Oral Contraceptive Study: OC use and health outcomes
• Birth cohort studies in India: Vellore Birth Cohort, etc.

---

COMPARISON: CASE-CONTROL vs COHORT

---

3. EXPERIMENTAL STUDIES (INTERVENTION STUDIES)

Key Distinction from Observational Studies

• In experimental studies, the investigator actively intervenes — allocates subjects to receive or not receive an intervention
• Strongest design for establishing causation (highest in hierarchy of evidence)
• Subject to extra ethical constraints since health of participants is at stake

Types

1. Randomized Controlled Trials (RCTs) — patients as subjects
2. Field Trials — healthy people as subjects
3. Community Trials — communities as units

---

A. RANDOMIZED CONTROLLED TRIAL (RCT)

Definition

Why RCT?

• Clinical impressions and anecdotal evidence can be misleading
• History of medicine shows many harmful treatments continued for decades without rigorous testing (bloodletting, purging)
• RCT has questioned validity of many widely used treatments: oral hypoglycaemics, varicose vein stripping, tonsillectomy, hospitalization of all MI patients, multiphasic screening

Basic Steps in Conducting an RCT (Park's 6 steps)

• Specifies: aims and objectives; research questions; inclusion/exclusion criteria; sample size; randomization method; intervention; outcome measures; statistical analysis plan; timeline
• Prevents bias; ensures consistency, especially in multi-centre trials
• Pilot study: May be conducted before finalizing protocol to test feasibility

• Reference (target) population: The wider population to whom results will be generalized
• Experimental population: Participants who are actually enrolled in the trial
• Inclusion criteria: Who can enter the trial
• Exclusion criteria: Who must be excluded (e.g., contraindications, pregnant women, children if not studied)
• Sample size: Must be adequate to detect clinically meaningful differences with statistical significance (power calculation); depends on expected effect size, significance level, power

• Random allocation of participants to study or control group
• Purpose: Ensures comparability of groups by distributing known AND unknown confounders equally between groups
• Methods:
  • Simple randomization: coin toss, random number tables, computer-generated
  • Block randomization: ensures equal group sizes in blocks (e.g., blocks of 4 or 6)
  • Stratified randomization: randomize within strata (e.g., by sex or age) to ensure balance in important subgroups
  • Cluster randomization: groups (clusters) are randomized together
• Allocation concealment: Concealing the randomization sequence until moment of allocation — prevents selection bias during enrollment

• Experimental group receives new treatment / intervention
• Control group receives:
  • Placebo (inert substance identical in appearance to treatment — most rigorous)
  • Standard/current treatment (when withholding treatment is unethical)
  • Different dose of the same treatment
• Blinding applied to reduce assessment bias

• When outcome is objective (e.g., death), blinding is less critical
• Blinding cannot be done in surgical trials, lifestyle interventions, etc. → use objective outcomes

• Inert substance identical in appearance, taste, and smell to active treatment
• Controls for placebo effect (improvement due to belief in treatment)
• Nocebo effect: Adverse effects from placebo

• Both groups followed for specified duration
• Compliance/adherence to intervention monitored
• Loss to follow-up (attrition): Must be minimized; differential dropout can bias results
• Cross-over between groups must be prevented
• Adverse events monitored and reported to Ethics Committee / DSMB (Data Safety Monitoring Board)
• Intention-to-treat (ITT) analysis: Analyse participants in the group they were originally allocated to, regardless of whether they completed treatment — preserves randomization benefits

• Compare incidence of outcomes between groups
• Positive results: Benefit — reduced incidence, severity, mortality, cost
• Negative results: Side effects, adverse events, complications (must be actively sought)
• Statistical significance testing (p-value, confidence intervals)
• NNT (Number Needed to Treat): Number of patients who need treatment for one additional person to benefit = 1/ARR (Absolute Risk Reduction)

Study Designs in RCTs

CONSORT Statement

• CONSORT (Consolidated Standards of Reporting Trials): International guidelines for reporting RCTs (flow diagram, 25-item checklist)
• Ensures transparency and completeness of RCT reporting

Ethical Considerations in RCT

1. Equipoise: Genuine uncertainty about which treatment is better — must exist before trial begins
2. Informed consent: Every participant must give voluntary, informed consent
3. Ethical Committee / IRB approval: Mandatory
4. DSMB (Data Safety Monitoring Board): Independent committee that reviews interim data; can stop trial early if clear harm or benefit
5. Helsinki Declaration (1964, revised): International ethical guidelines for medical research on human subjects
6. Registration: RCTs must be registered prospectively (Clinical Trials Registry — India: CTRI; International: ClinicalTrials.gov)

---

B. FIELD TRIAL

Definition

Purpose

• Test preventive interventions in at-risk but currently disease-free individuals
• Evaluate vaccines, preventive drugs, dietary supplements, screening programmes

Key Features

• Participants are healthy people (not patients) — unlike RCTs
• Conducted in field settings (homes, schools, communities)
• Usually much larger than clinical trials (because disease incidence is low in healthy people → need large numbers to observe enough cases)
• More expensive and logistically complex

Steps

Classic Examples of Field Trials

Measures Used

• Protective efficacy (PE) / Vaccine efficacy:

• PE = 0%: No protection
• PE = 100%: Complete protection

---

C. COMMUNITY TRIAL (COMMUNITY INTERVENTION STUDY)

Definition

Also Called

• Community intervention study
• Community-based trial
• Group randomized trial
• Cluster randomized trial

Purpose

• Test interventions that are applied to whole communities (cannot be applied to individuals in isolation)
• Water fluoridation, sanitation improvement, mass media campaigns, environmental changes, health education programmes, fortification of food supply

Key Features

• Randomization: Communities (villages, districts, schools, worksites) are randomly assigned to intervention or control
• Communities in intervention group receive the programme
• Communities in control group do not (or receive standard care)
• Individual consent may be difficult or impossible to obtain for community-wide measures
• Contamination between groups possible if communities are geographically close
• Analysis: Must account for clustering (individuals within same community are more similar to each other than to those in other communities) — Intra-cluster correlation (ICC)

Classic Examples

Advantages

1. Tests interventions as they would be applied in real-world public health practice
2. Can capture community-level effects (herd immunity, social norm changes)
3. Avoids contamination of individual-level assignment (if communities are geographically separated)
4. Essential when the intervention cannot be randomized at individual level (e.g., water fluoridation affects all who drink from the supply)

Disadvantages

1. Very expensive — large scale, many communities
2. Limited number of units (communities) → reduced statistical power
3. Ethical issues — entire communities receive or are denied an intervention; individual consent difficult
4. Contamination between communities if they are geographically close
5. Cannot control for all confounders between communities
6. Analysis requires special statistical methods (multilevel modelling, accounting for ICC)

---

COMPARISON: THREE TYPES OF EXPERIMENTAL STUDIES

---

HIERARCHY OF EVIDENCE (Evidence-Based Medicine)

1. Systematic Reviews + Meta-analyses (of RCTs)
2. Randomized Controlled Trials (RCTs)
3. Cohort Studies
4. Case-Control Studies
5. Cross-Sectional Studies
6. Ecological Studies
7. Case Reports / Case Series
8. Expert Opinion / Editorials

---

KEY FORMULAE SUMMARY

---

QUICK COMPARISON TABLE (All Study Designs)

---

KEY TERMINOLOGY

---